A man with recurrent hypovolemic shock on anti-programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy

被引：3

作者：

Lee, Seo Young ^{[1
]}

Kim, Min Hwan ^{[1
]}

Jang, Mi ^{[2
]}

Park, Yehyun ^{[3
]}

Cho, Byoung Chul ^{[1
]}

机构：

[1] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Div Med Oncol,Dept Internal Med, 50-1 Yonsei Ro, Seoul 03722, South Korea

[2] Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea

[3] Yonsei Univ, Coll Med, Dept Internal Med, Inst Gastroenterol, Seoul, South Korea

来源：

EUROPEAN JOURNAL OF CANCER | 2018年 / 104卷

关键词：

D O I：

10.1016/j.ejca.2018.09.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：104 / 107

页数：4

共 50 条

[21] Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer
Koyama, Junji
Horiike, Atsushi
Yoshizawa, Takahiro
Dotsu, Yosuke
Ariyasu, Ryo
Saiki, Masafumi
Sonoda, Tomoaki
Uchibori, Ken
Nishikawa, Shingo
Kitazono, Satoru
Yanagitani, Noriko
Ninomiya, Hironori
Ishikawa, Yuichi
Nishio, Makoto
JOURNAL OF THORACIC DISEASE, 2019, 11 (05) : 1919 - +
[22] Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer
Rivera, Noelia
Boada, Aram
Isabel Bielsa, M.
Teresa Fernandez-Figueras, M.
Carcereny, Enric
Teresa Moran, M.
Ferrandiz, Carlos
JAMA DERMATOLOGY, 2017, 153 (11) : 1162 - 1165
[23] Effects of combined chemotherapy and anti-programmed cell death protein 1 treatment on peripheral neuropathy and neuroinflammation in mice
Livni, Lital
Keating, Brooke A.
Fiore, Nathan T.
Lees, Justin G.
Goldstein, David
Moalem-Taylor, Gila
PAIN, 2022, 163 (01) : 110 - 124
[24] Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communication
Aya, Francisco
Gonzalez-Navarro, E. Azucena
Martinez, Clara
Carcelero, Esther
Arance, Ana
IMMUNOTHERAPY, 2021, 13 (09) : 745 - 752
[25] Synergy between glutamate modulation and anti-programmed cell death protein 1 immunotherapy for glioblastoma
Medikonda, Ravi
Choi, John
Pant, Ayush
Saleh, Laura
Routkevitch, Denis
Tong, Luqing
Belcaid, Zineb
Kim, Young Hoon
Jackson, Christopher M.
Jackson, Christina
Mathios, Dimitrios
Xia, Yuanxuan
Shah, Pavan P.
Patel, Kisha
Kim, Timothy
Srivastava, Siddhartha
Huq, Sakibul
Ehresman, Jeff
Pennington, Zach
Tyler, Betty
Brem, Henry
Lim, Michael
JOURNAL OF NEUROSURGERY, 2022, 136 (02) : 379 - 388
[26] Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
B Homet Moreno
A Ribas
British Journal of Cancer, 2015, 112 : 1421 - 1427
[27] Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma
Qin, Lei
Li, Xiang
Stroiney, Amanda
Qu, Jinrong
Helgager, Jeffrey
Reardon, David A.
Young, Geoffrey S.
NEURORADIOLOGY, 2017, 59 (02) : 135 - 145
[28] Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
Moreno, B. Homet
Ribas, A.
BRITISH JOURNAL OF CANCER, 2015, 112 (09) : 1421 - 1427
[29] Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma
Lei Qin
Xiang Li
Amanda Stroiney
Jinrong Qu
Jeffrey Helgager
David A. Reardon
Geoffrey S. Young
Neuroradiology, 2017, 59 : 135 - 145
[30] Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
Ricciuti, Biagio
Naqash, Abdul Rafeh
Naidoo, Jarushka
Sehgal, Kartik
Miller, Adam
Kehl, Kenneth
Venkatraman, Deepti
Sands, Jacob
Lamberti, Giuseppe
Recondo, Gonzalo
Zhang, Jiajia
Macherla, Shravanti
Baig, Sameer
Walker, Paul
Rangachari, Deepa
Gainor, Justin F.
Costa, Daniel B.
Rizvi, Naiyer
Sholl, Lynette M.
Nishino, Mizuki
Henick, Brian
Farago, Anna F.
Awad, Mark M.
JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (04):

← 1 2 3 4 5 →